US Pharm. 2015;40(6):21.

Milwaukee, WI—An analysis of data from the FDA Adverse Events Reporting System (FAERS) has found that blood-clotting disorders tied to the opioid pain medication Opana have grown since introduction of its new abuse-deterrent formulation. The newer version of oxymorphone was intended to be more difficult to abuse, with an outer coating that makes it hard to crush or snort; however, abusers have found a way to melt it down and inject it. Since the reformulation in 2012, blood-clotting disorders associated with abuse of the drug have grown from four to 53 cases annually. The drug’s manufacturer, Endo Pharmaceuticals, is “unaware of any reports that this rare condition has occurred in any individuals
who use the product appropriately.”

To comment on this article, contact